• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

CIRSE 2017 Round-up: Delcath touts second-gen hemofiltration system in percutaneous hepatic perfusion

September 19, 2017 By Sarah Faulkner

Delcath SystemsDelcath Systems (NSDQ:DCTH) touted data today from a study of its second-generation hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan hydrochloride.

The New York-based company presented the results from its study at the Cardiology and Interventional Radiology of Europe annual meeting in Copenhagen, Denmark.

The investigational product, an injectable melphalan hydrochloride for use with Delcath’s hepatic delivery system, is designed to administer high-dose chemotherapy to the liver while limiting systemic exposure and side effects.

The study assessed filtration efficiency and hematologic side effects in seven patients who received PHP procedures with Delcath’s Gen2 Chemosat system.

Data from the study showed that the Gen2 Chemosat boasts an overall efficiency of 86%, with efficiency highest at the time of peak concentration of melphalan in the blood and declining in line with melphalan blood concentration. The company said that these results are better than those published with the 1st-gen Chemosat system.

The researchers also noted that there was no mortality, no severe bleeding complications and no hypotensive cardiac or cerebral events.

“This study provides good external confirmation of the filtration efficiency capability and consistent performance seen with the Gen2 Chemosat, and is consistent with what we are seeing in the commercial setting,” Delcath president & CEO Jennifer Simpson said in prepared remarks. “This study also indicates that the hematologic side effects of treatment with Chemosat are manageable. We look forward to validating these observations in our registration trials, which include robust evaluation of the pharmacokinetic characteristics of the PHP procedure.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Pages: Page 1 Page 2 Page 3

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Biotronik, Boston Scientific, Delcath Systems Inc.

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS